Cost-Effectiveness Analysis of Evolocumab in Adult Patients with Atherosclerotic Cardiovascular Disease in Canada
Authors:
Open Access
- 23 May 2022
- journal article
- research article
- Published by Springer Nature in Advances in Therapy
- Vol. 39 (7) , 3262-3279
Abstract
Introduction To evaluate the cost-effectiveness of evolocumab when added to standard of care lipid-lowering treatment (LLT) for patients with atherosclerotic cardiovascular disease (ASCVD) who cannot adequately control their low-density lipoprotein cholesterol (LDL-C) despite optimized LLT in Canada. Methods An incremental cost-utility analysis was conducted using a Markov cohort state transition model adapted to the Canadian setting. Analyses were conducted from a public health and societal perspective using a lifetime time horizon for Canada. Scenario analyses were conducted on the basis of recommendations from the 2021 Canadian Cardiovascular Society (CCS) dyslipidemia guidelines. Results In ASCVD patients with prior myocardial infarction (MI) and baseline LDL-C ≥ 1.8 mmol/L, adding evolocumab to optimized statin therapy with or without ezetimibe is associated with an incremental cost per quality-adjusted life year (QALY) gained of $66,453 CAD. Furthermore, for every 100 patients treated with evolocumab for lifetime, adding evolocumab to optimized LLT will prevent approximately 52 cardiovascular (CV) events, of which seven would be fatal. The results are generally robust using univariate and simultaneous variation in model input parameters. Scenario analyses for patient populations as per the CCS guidelines suggest that evolocumab added to optimized LLT may be considered cost-effective, given an incremental cost-effectiveness ratio (ICER) threshold of CAD$100,000 per QALY gained. Limitations associated with this analysis should be interpreted in the context of data and modeling assumptions used. Conclusion Overall, this analysis supports reimbursement of evolocumab by payers in patients with ASCVD who cannot reach LDL-C thresholds despite optimized LLT to reduce unnecessary fatal and non-fatal CV events.Keywords
Funding Information
- Amgen Canada
This publication has 38 references indexed in Scilit:
- A Century of Cholesterol and Coronaries: From Plaques to Genes to StatinsCell, 2015
- A mediation approach to understanding socio-economic inequalities in maternal health-seeking behaviours in EgyptBMC Health Services Research, 2015
- 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsCirculation, 2014
- Low self-estimated quality of life after myocardial infarction and future cardiovascular riskInternational Journal of Cardiology, 2012
- Familial Hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patientsJournal of Clinical Lipidology, 2011
- High total serum cholesterol, medication coverage and therapeutic control: an analysis of national health examination survey data from eight countriesBulletin of the World Health Organization, 2011
- Health-Related Quality of Life in Patients with a History of Myocardial Infarction and StrokeCerebrovascular Diseases, 2010
- Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trialsThe Lancet, 2010
- Quality of life several years after myocardial infarction: comparing the MONICA/KORA registry to the general populationEuropean Heart Journal, 2008
- Health-related quality of life in women and men one year after acute myocardial infarctionQuality of Life Research, 2005